Evidence map›Paper›PMID 42729758›Full record

ArticleMaterials today. Bio2026

AgBiS

Litao Liu, Yechun Jiang, Xianyu Huang, Yongqi Gou, Ling Xu, Hui Shen, Ming Hu, Weinan Zhang, Wanni Wang, Haisheng Qian and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Litao LiuSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Yechun JiangSchool of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230022, China.
Xianyu HuangSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Yongqi GouSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Ling XuSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Hui ShenSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Ming HuSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Weinan ZhangSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Wanni WangSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Haisheng QianSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.
Lingling XuSchool of Biomedical Engineering, Anhui Medical University, Hefei, 230012, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a non-invasive antitumor therapy, photothermal therapy (PTT) faces significant hurdles in clinical translation, due to the limited tissue penetration of photothermal agents and the limited efficacy against distant metastases. Although engineered bacteria hold promise for addressing these challenges owing to their intrinsic tumor-targeting capability and immunogenicity, their intravenous administration is often hindered by limitations such as premature drug shedding and potential systemic toxicity. To overcome these challenges, we designed an in situ implantable, multifunctional local delivery system AEM IMP (an implant containing engineered bacteria ABSE and manganese ions). By co-loading Mn

Indexed as

Engineered bacteriaImmunotherapyPhotothermal therapyTumor implant

Identifiers

PMID42729758
PMCPMC13563588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.